Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action

被引：448
作者：
Pescovitz, MD [1 ]
机构：
[1] Indiana Univ, Dept Surg, Indianapolis, IN 46204 USA
[2] Indiana Univ, Dept Microbiol Immunol, Indianapolis, IN 46204 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2006年 / 6卷 / 05期
关键词：
anti-CD20; mechanism; pharmacokinetics; rituximab; transplant;
D O I：
10.1111/j.1600-6143.2006.01288.x
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Rituximab, chimeric anti-human CD20, is approved for treatment of B-cell lymphoma in adults. It is being used experimentally in other various immune-related diseases such as immune thrombocytopenic purpura, systemic lupus erythematosus, myasthenia gravis and rheumatoid arthritis. In transplant recipients, it is used for treatment of post-transplant lymphoproliferative disease, to anecdotally reduce pre-formed anti-HLA and anti-ABO antibodies and for the prevention and treatment of acute rejection. This article primarily reviews the science behind rituximab: its history, pharmacokinetics and potential mechanism of action. A need for controlled clinical trials is clearly indicated before the widespread use of this drug in transplant.
引用
收藏
页码：859 / 866
页数：8
相关论文
共 91 条
[1]   Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses [J].
Agarwal, A ;
Vieira, CA ;
Book, BK ;
Sidner, RA ;
Fineberg, NS ;
Pescovitz, MD .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (08) :1357-1360
[2]  
AGARWAL A, 2005, AM J TRANSPLANT S11, V5, P1239
[3]   Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab [J].
Alausa, M ;
Almagro, U ;
Siddiqi, N ;
Zuiderweg, R ;
Medipalli, R ;
Hariharan, S .
CLINICAL TRANSPLANTATION, 2005, 19 (01) :137-140
[4]   The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].
Anolik, JH ;
Campbell, D ;
Felgar, RE ;
Young, F ;
Sanz, I ;
Rosenblatt, J ;
Looney, RJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459
[5]   Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: A case report [J].
Aranda, JM ;
Scornik, JC ;
Normann, SJ ;
Lottenberg, R ;
Schofield, RS ;
Pauly, DF ;
Miles, M ;
Hill, JA ;
Sleasman, JW ;
Skoda-Smith, S .
TRANSPLANTATION, 2002, 73 (06) :907-910
[6]   Use of rituximab to decrease panel-reactive antibodies [J].
Balfour, IC ;
Fiore, A ;
Graff, RJ ;
Knutsen, AP .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (05) :628-630
[7]   F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins:: a novel effector function of immunoglobulins [J].
Basta, M ;
Van Goor, F ;
Luccioli, S ;
Billings, EM ;
Vortmeyer, AO ;
Baranyi, L ;
Szebeni, J ;
Alving, CR ;
Carroll, MC ;
Berkower, I ;
Stojilkovic, SS ;
Metcalfe, DD .
NATURE MEDICINE, 2003, 9 (04) :431-438
[8]   Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing [J].
Bearden, CM ;
Book, BK ;
Sidner, RA ;
Pescovitz, MD .
JOURNAL OF IMMUNOLOGICAL METHODS, 2005, 300 (1-2) :192-199
[9]   Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174 [J].
Bearden, CM ;
Agarwal, A ;
Book, BK ;
Vieira, CA ;
Sidner, RA ;
Ochs, HD ;
Young, M ;
Pescovitz, MD .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (01) :50-57
[10]   Rituximab as treatment for refractory kidney transplant rejection [J].
Becker, YT ;
Becker, BN ;
Pirsch, JD ;
Sollinger, HW .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :996-1001
12345678910